Goldman Sachs analyst Paul Choi downgraded the rating on Lantheus to a Hold today, setting a price target of $77.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paul Choi has given his Hold rating due to a combination of factors affecting Lantheus’s current market performance. The company has faced ongoing pricing pressure on its product Pylarify, which has contributed to a less optimistic outlook. Additionally, the slower-than-expected uptake of Alzheimer’s disease treatments has further dampened growth prospects.
Furthermore, Lantheus’s recent acquisitions have introduced uncertainty regarding the company’s future growth drivers, making it challenging to predict its trajectory. While the risk and reward appear balanced at present, a more robust recovery in the stock price is dependent on clearer indications of organic growth. Consequently, Paul Choi has downgraded the stock to a Neutral rating with a revised price target of $77.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LNTH in relation to earlier this year.